View Cart  

J&J Suspends Three Trials of Experimental Dermatitis Drug Due to Adverse Events

A A
Johnson & Johnson (J&J) has halted two Phase II clinical trials and withdrawn plans for another after two patients receiving an experimental dermatitis drug experienced serious adverse events.

To View This Article:

Login

Subscribe To Drug Industry Daily